Storage-stable ophthalmic composition
View Patent ↗The present invention relates to a drop-forming, storage stable, multiphase, ophthalmic composition comprising at least one liquid aqueous phase and at least one liquid hydrophobic phase, characterized in that it is emulsifier-free as well as buffer-free and comprises hyaluronic acid and/or hyaluronate.
1. A storage stable, multiphase, ophthalmic composition comprising at least one liquid aqueous phase and at least one liquid hydrophobic phase, characterized in that:
the composition is emulsifier-free;
the composition is buffer-free;
the composition is free of a phosphate salt;
the composition exhibits a viscosity of less than 250 mPa·s at 20° C.;
wherein the at least one liquid aqueous phase comprises water and exhibits one or more of a pH value of from 6 to 8 and an osmolality of from 200 to 400 mosmol/kg, and the at least one liquid hydrophobic phase comprises an ophthalmic acceptable oil; and
wherein the composition comprises hyaluronic acid and/or hyaluronate, characterized in that the hyaluronic acid and/or hyaluronate exhibits a molecular weight M w of from 50,000 to 1,000,000 g/mol.
2. The composition according to claim 1 , characterized in that the composition comprises hyaluronic acid and/or hyaluronate in an amount of at least 0.001 wt. % to 5 wt. %, based on the total weight of the composition.
3. The composition according to claim 1 , characterized in that the hyaluronate is selected from the group consisting of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, and mixtures thereof.
4. The composition according to claim 1 , characterized in that the composition comprises the liquid aqueous phase as a continuous phase, and the liquid hydrophobic phase as droplets dispersed therein.
5. The composition according to claim 1 , characterized in that the composition further comprises at least one polymeric gel-forming component.
6. The composition according to claim 5 , wherein the at least one polymeric gel-forming component comprises at least one of a polyacrylic acid and a polymeric polyacrylic acid derivative.
7. The composition according to claim 1 , wherein the ophthalmic acceptable oil is a triglyceride.
8. The composition according to claim 1 , characterized in that the composition further comprises an isotonicity agent.
9. The composition according to claim 8 , wherein the isotonicity agent is selected from the group consisting of dextrose, glycerin, propylene glycol, sorbitol, mannitol, urea, polyethylene glycol, boric acid, magnesium sulfate, zinc sulfate, sodium chloride, potassium chloride, calcium chloride, sodium sulfate, and mixtures thereof.
10. The composition according to claim 1 , wherein the at least one liquid aqueous phase exhibits a pH value of from 7.1 to 7.8 and an osmolality of from 260 to 320 mosmol/kg.
11. The composition according to claim 10 , characterized in that the composition comprises the ophthalmic acceptable oil in an amount of from 0.05 to 10 wt. %, based on the total weight of the composition.
12. The composition according to claim 1 , characterized in that the composition comprises:
0.15 to 0.3 wt. %, based on the total weight of the composition, of sodium hyaluronate,
0.15 to 0.25 wt. %, based on the total weight of the composition, of a medium-chain triglyceride,
0.05 to 0.1 wt. %, based on the total weight of the composition, of a carbomer,
1.5 to 7 wt. %, based on the total weight of the composition, of an isotonicity agent,
sodium hydroxide for pH adjustment, and
q.s. ad 100 wt. % water.
13. The composition according to claim 1 , characterized in that the composition is in form of an eye lid spray, an eye bath, an eye wash solution, or eye drops.
14. A container comprising a drop-forming, storage stable, multiphase, ophthalmic composition, wherein the container is a single-dose container or a multi-dose container; wherein the drop-forming, storage stable, multiphase, ophthalmic composition comprises at least one liquid aqueous phase and at least one liquid hydrophobic phase, characterized in that:
the composition is emulsifier-free;
the composition is buffer-free;
the composition is free of a phosphate salt;
the composition exhibits a viscosity of less than 250 mPa·s at 20° C.;
wherein the at least one liquid aqueous phase comprises water and exhibits one or more of a pH value of from 7.1 to 7.8 and an osmolality of from 260 to 320 mosmol/kg, and the at least one liquid hydrophobic phase comprises an ophthalmic acceptable oil; and
wherein the composition comprises hyaluronic acid and/or hyaluronate, characterized in that the hyaluronic acid and/or hyaluronate exhibits a molecular weight M w of from 50,000 to 1,000,000 g/mol.
15. The container according to claim 14 , wherein the composition comprises:
0.15 to 0.3 wt. %, based on the total weight of the composition, of sodium hyaluronate,
0.15 to 0.25 wt. %, based on the total weight of the composition, of a medium-chain triglyceride,
0.05 to 0.1 wt. %, based on the total weight of the composition, of a carbomer,
1.5 to 7 wt. %, based on the total weight of the composition, of an isotonicity agent,
sodium hydroxide for pH adjustment, and
q.s. ad 100 wt. % water.
16. The composition according to claim 1 , wherein the hyaluronic acid and/or hyaluronate is present in the composition in an amount of 0.15 to 0.3 wt. %, based on the total weight of the composition.
17. The composition according to claim 1 , exhibiting a viscosity of less than 200 mPa·s at 20° C.
18. The container according to claim 14 , wherein the composition comprises 0.15 to 0.3 wt. %, based on the total weight of the composition, of hyaluronic acid and/or hyaluronate.
19. The container according to claim 14 , characterized in that the composition further comprises at least one polymeric gel-forming component.
20. The container according to claim 19 , wherein the at least one polymeric gel-forming component comprises at least one of a polyacrylic acid and a polymeric polyacrylic acid derivative.